par Boeynaems, Jean-Marie 
;van Giezen, Hans;Savi, P.;Herbert, Jean-Marc
Référence Current opinion in investigational drugs, 6, 3, page (275-282)
Publication Publié, 2005-03
;van Giezen, Hans;Savi, P.;Herbert, Jean-MarcRéférence Current opinion in investigational drugs, 6, 3, page (275-282)
Publication Publié, 2005-03
Article révisé par les pairs
| Résumé : | The dual role of P2Y1 and P2Y12 receptors in platelet aggregation by ADP has been firmly established, based on the action of selective inhibitors, gene targeting in mice and human genetic evidence. Both of these receptor subtypes constitute targets for antithrombotic agents, and compounds with a dual action might also be of interest. However, the agents currently on the market (ticlopidine and clopidogrel), or known to be in development (cangrelor, AZD-6140 and prasugrel), all target the P2Y12 receptor. The thienopyridines (ticlopidine, clopidogrel and prasugrel) irreversibly inactivate the P2Y12 receptor via the covalent binding of an active metabolite generated in the liver, while the other compounds are competitive antagonists. Cangrelor, an ATP derivative, is suitable for intravenous perfusion, whereas AZD-6140 is in clinical development as an orally active agent. |
